Switzerland

Transformative times: Where next for Switzerland’s insurers?

Swiss insurers are no strangers to change. New technologies and ways of working are transforming our industry. In this series of articles, we share our insights into what will be the key challenges and opportunities over the coming year, and what Switzerland’s insurers need to do to stay ahead.
3

Circumvention of the AEoI: New OECD rules against fictional residences

In March 2018, the OECD accepted the Mandatory Disclosure Rules for CRS Avoidance Arrangements and Opaque Offshore Structures. In parallel, the OECD launched a further initiative called “Preventing abuse of residence by investment schemes to circumvent the CRS”, aimed at fictitious tax residences based on investments.
5

Clarity on Swiss Taxes – Beyond limits

When it comes to tax and business, Switzerland remains competitive on the global tax stage, as confirmed by KPMG’s latest “Swiss Tax Report 2018” which compares corporate and income tax rates in 130 countries as well as all 26 cantons.
4

Projet Fiscal 17 – Le Conseil fédéral publie le message pour le Parlement

En date du 21 mars 2018, le Conseil fédéral a présenté le message relatif au Projet Fiscal 17 (ci-après «PF 17»). Le Conseil fédéral a souligné la nécessité du PF 17 afin de maintenir la compétitivité de la Suisse tout en garantissant la création de valeurs, d’emplois ainsi qu’en préservant les recettes fiscales.
4

Tax Proposal 17 – Federal Council releases dispatch to parliament

On Wednesday 21 March 2018, the Swiss Federal Council published its dispatch on the Tax Proposal 17. The federal Council clearly stated the necessity of the Tax Proposal 17 in order to maintain Switzerland’s position as a competitive business location, to support value creation, jobs and tax revenues in Switzerland.
17

EU Medical Device Regulation: What’s the impact?

Following various incidents in recent years, the control mechanisms for medical devices are being tightened throughout Europe with the new EU Medical Device Regulation (MDR) and In Vitro Diagnostics Regulation (IVDR). What is the impact of these EU regulations for Switzerland and how do you ensure compliance on your end by the time the transition period ends?
4